Business
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual inv
About this update from Cue Biopharma, Inc.
[{"type":"image","alt":"Cue Biopharma, Inc.","displaySize":"","headline":null,"caption":"Cue Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/fc5f3951698cbec35d4307d642ba0cac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wN2RaVoKznrUsI8vRAvjSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fc5f3951698cbec35d4307d642ba0cac","width":300,"height":110}},"lazy":false},{"type":"text","content":"Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event","length":81,"tagName":"p"},{"type":"text","content":"Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD","length":93,"tagName":"p"},{"type":"text","content":"BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET. To register, click here.","length":411,"tagName":"p"},{"type":"text","content":"The virtual event will feature key opinion leaders (KOLs) Richard DiPaolo, PhD (Saint Louis University) and Andrew Cope, MD, PhD (Centre for Rheumatic Diseases, King's College London). Together with Cue Biopharma's management, they will discuss the Company’s differentiated biologics platform, which has the unique potential to selectively activate and expand disease relevant T cells, with clinical tolerability from the Company’s Phase 1 clinical trials of CUE-101 and CUE-102.","length":497,"tagName":"p"},{"type":"text","content":"In addition, the event will feature a review of the CUE-400 series, including new preclinical proof-of-concept data for lead candidate, CUE-401, aimed at transforming the standard of care for autoimmune diseases and inflammation. Cue Biopharma will also provide an overview of the CUE-500 program, including CUE-501, recently partnered with Boehringer Ingelheim, engineered to leverage anti-viral killer T cells for autoimmune diseases and cancer. The Company will also provide updates on its CUE-100 series clinical oncology programs."...